Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 6/20 | 0.81 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.59 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CTSA | P10619 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26264461 | 0.89 | SUCNR1 (1.00) | SUCNR1SCN10AABL1SCN9ACTSA | |
| SCHEMBL26263291 | 0.88 | SUCNR1 (0.63) | SUCNR1SCN9ACNR2CNR1CTSA | |
| SCHEMBL26263279 | 0.87 | SUCNR1 (0.61) | SUCNR1SCN9ACNR2CTSA | |
| SCHEMBL6098304 | 0.87 | SUCNR1 (0.76) | SUCNR1SCN10AABL1SCN9ACNR2 | |
| SCHEMBL26263580 | 0.86 | SUCNR1 (0.60) | SUCNR1SCN9ACNR2CTSA | |
| SCHEMBL26263268 | 0.84 | SCN9A (0.60) | SUCNR1SCN9ACNR2CNR1CTSA | |
| SCHEMBL26263294 | 0.84 | SUCNR1 (0.60) | SUCNR1SCN9ACNR2CTSA | |
| SCHEMBL25003803 | 0.81 | SUCNR1 (0.67) | SUCNR1SCN10AABL1SCN9A | |
| SCHEMBL6098309 | 0.80 | SUCNR1 (0.75) | SUCNR1CTSA | |
| SCHEMBL26263281 | 0.79 | SUCNR1 (0.52) | SUCNR1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | UNIV NEW YORK (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | SUCNR1, SYNGR2, TSPO | SUCNR1 1/4885SCN10A 751/4885ABL1 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.